Latest News

Sign up for our RSS Feed.
2 Oct 2014 NeurOp Receives Milestone Payment as Bristol-Myers Squibb Nominates NMDA Recepto ... Read More
29 Sep 2014 NeurOp Awarded NIH Grant for Alzheimer’s Disease Drug Research Read More
Management Team

George (Barney) Koszalka, Ph.D.

President and Chief Executive Officer George (Barney) Koszalka, Ph.D., joined NeurOp in 2010 as president and CEO to lead the company in a new growth phase to advance its novel and proprietary small molecules. Dr. Koszalka is a senior executive with more than 35 years of leadership experience in global pharmaceutical drug development at Burroughs Wellcome, Glaxo Wellcome, GlaxoSmithKline, Trimeris, Inc., and Argolyn Biosciences. He has extensive knowledge of pharmaceutical R&D, joint ventures, business development, product development and medical marketing. Dr. Koszalka has initiated and advanced numerous preclinical and clinical projects and has contributed in a significant manner to the discovery, development and/or lifecycle management of 12 marketed drugs. He serves as an editor for Current Opinion in Investigational Drugs and chairs the scientific advisory board for the Consortium for Parasitic Drug Development, funded by the Bill & Melinda Gates Foundation. He received his Ph.D. in biochemistry from North Carolina State University.

Robert Zaczek, Ph.D.

Chief Scientific Officer Robert Zaczek joined the NeurOp leadership team in 2012 as its chief scientific officer. Dr. Zaczek has more than 20 years of experience in neuroscience drug discovery and pipeline development at Bristol-Myers Squibb Company and DuPont Pharmaceuticals Company. Prior to joining NeurOp, he was executive director of psychiatry drug discovery at Bristol-Myers Squibb. During his tenure, he headed a multidisciplinary scientific group, which contributed to numerous discovery programs that led to the nomination of clinical candidates for affective disorders, schizophrenia and Alzheimer’s disease. Dr. Zaczek earned his doctorate in pharmacology from Johns Hopkins University School of Medicine and completed a postdoctoral fellowship at the Addiction Research Center of the National Institute on Drug Abuse.

Lee H. Latimer, Ph.D.

Head of Chemistry Lee Latimer joined NeurOp in 2014 to lead its chemistry program. He has over 30 years’ experience in medicinal, process and analytical chemistry. He was most recently a consultant to the pharmaceutical and biotechnology industries. Prior to that, he was senior director of process and analytical chemistry at Elan Pharmaceuticals. He successfully led in-house and outsourced oversight and development of GMP routes to five clinical candidates in its Alzheimer’s disease and multiple sclerosis programs. Dr. Latimer is also an inventor of semagacestat, which reached phase III clinical trials for Alzheimer’s disease in collaboration with Eli Lilly. He received his Ph.D. in organic chemistry from the University of Wisconsin under the mentorship of B.M. Trost and held an NIH Fellowship with W.G. Dauben at the University of California at Berkeley and C.J. Sih at the University of Wisconsin at Madison. He is an American Chemical Society Fellow.

Scott Myers, Ph.D.

Director of Drug Discovery Scott Myers joined NeurOp as its director of drug discovery in 2006. He has helped lead efforts to develop subunit-selective NMDA receptor antagonists, from discovery through lead optimization, as potential clinical candidates for the treatment of cerebral ischemia, including subarachnoid hemorrhage, pain, and depression. Dr. Myers trained in the laboratory of Dr. Ray Dingledine and collaborated with Dr. Stephen Traynelis on the evaluation of NR2B-selective antagonists. He received his Ph.D. in pharmacology from the University of North Carolina at Chapel Hill.